Kura Oncology (KURA) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Savara (SVRA) has outperformed Kura Oncology (KURA) over the past year, gaining 43.9% versus a gain of 3.4%. Over five years, SVRA leads with a +281.4% price change compared with -41.2% for KURA. Savara is the larger company by market cap ($1.01 billion vs $943.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | SVRA |
|---|---|---|
| Share price | $10.60 | $4.92 |
| Market cap | $942.98M | $1.01B |
| 1-day change | +0.76% | +1.86% |
| YTD return | +2.02% | -18.41% |
| 1-year return | +3.41% | +43.86% |
| 5-year return | -41.18% | +281.40% |
| EPS (TTM) | $-3.37 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | — |
| Revenue growth (YoY) | +25.24% | — |
| Net income (latest FY) | $-278.67M | $-118.84M |
| Operating margin | -449.94% | — |
| Net margin | -412.95% | — |
| 52-week high | $13.90 | $7.01 |
| 52-week low | $7.36 | $3.35 |
| Distance from 52-week high | -23.74% | -29.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +200.47% | +124.80% |
| Average volume | 1.77M | 1.83M |
| Shares outstanding | 88.96M | 205.46M |
| Employees | 260 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SVRA has outperformed KURA by 40.4 percentage points over the past year.
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
KURA vs SVRA FAQ
Which is bigger, Kura Oncology or Savara?
Savara (SVRA) is larger, with a market capitalization of $1.01B compared with $942.98M for Kura Oncology (KURA).
Which stock has performed better over the past year, KURA or SVRA?
SVRA returned +43.86% over the past 12 months, compared with +3.41% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.